Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 5/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8789607 | 0.89 | ABCG2 (0.60) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8789555 | 0.88 | ABCG2 (0.77) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8790186 | 0.88 | ABCG2 (0.59) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8790265 | 0.87 | ABCG2 (0.60) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8790235 | 0.87 | ABCG2 (0.56) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8789736 | 0.86 | ABCG2 (0.55) | ABCG2ABCB1MAPTMEN1KMT2A | |
| SCHEMBL8790651 | 0.86 | ABCG2 (0.57) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8790484 | 0.86 | ABCG2 (0.57) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8789297 | 0.85 | ABCG2 (0.56) | ABCG2ABCB1MAPTLMNAL3MBTL1 | |
| SCHEMBL8788465 | 0.85 | ABCG2 (0.72) | ABCG2ABCB1LMNAL3MBTL1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0569380-B1 | ACRIDINE DERIVATIVES | GLAXO LAB SA (FR) | 1997-05-28 | — | — | EP | disclosed |
| US-5604237-A | IMPROVE OR INCREASE EFFICACY OF ANTITUMOR AGENT, INCREASE OR RESTORE SENSITIVITY OF TUMOR TO ANTITUMOR AGENT, REVERSE OR REDUCE RESISTANCE OF TUMOR TO ANTITUMOR AGENT | LABORATOIRES GLAXO SA (FR) | 1997-02-18 | — | — | US | disclosed |
| EP-0494623-A1 | Acridine derivatives | LABORATOIRES GLAXO SA (FR) | 1992-07-15 | — | — | EP | disclosed |